BMRA: Biomerica, Inc. Stock

by  •  • Comments Off on BMRA: Biomerica, Inc. Stock

SIC 2835 – In Vitro and In Vivo Diagnostic Substances

Valuation
Market Cap ($M) 11.91
Enterprise Value ($M) 9.54
Book Value ($M) 5.11
Book Value / Share 0.28
Price / Book 2.33
NCAV ($M) 3.79
NCAV / Share 0.21
Price / NCAV 3.15

Profitability (mra)
Return on Invested Capital (ROIC) -0.98
Return on Assets (ROA) -0.54
Return on Equity (ROE) -0.72

Liquidity (mrq)
Quick Ratio 2.22
Current Ratio 3.17

Balance Sheet (mrq) ($M)
Current Assets 5.95
Assets 7.27
Liabilities 2.16
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-11 13G Wasatch Advisors Inc 0.00
11-14 13G/A Granahan Investment Management Inc/ma 3.14 -51.28

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUA
2024-10-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT
2024-08-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section
2024-04-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 29, 2024 or ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-10 38,917 265,738 14.64
2025-03-07 46,452 162,090 28.66
2025-03-06 40,725 193,050 21.10
2025-03-05 16,785 209,254 8.02
2025-03-04 38,288 305,740 12.52

(click for more detail)

Similar Companies
BFRI – Biofrontera Inc. BGM – BGM Group Ltd.
BIVI – BioVie Inc. BNTC – Benitec Biopharma Inc.
BOLT – Bolt Biotherapeutics, Inc.


Financial data and stock pages provided by
Fintel.io